Tangent90 announces strategic collaboration with NEJM Group

London, United Kingdom – 8th September 2022: Tangent90 Ltd, a leading provider of digital solutions to help pharmaceutical companies improve their engagement with healthcare professionals (HCPs), has entered into a strategic collaboration with NEJM Group publications (New England Journal of Medicine, NEJM Evidence, NEJM Catalyst, NEJM Journal Watch).

The New England Journal of Medicine (NEJM) is recognised as the world’s leading medical journal. With its long history of publishing trusted, impactful, peer-reviewed original content, NEJM will use Tangent90’s Trustrack links to support digital rights management and seamless access to content for its pharmaceutical clients looking to reach HCPs.  Trustrack links deliver an optimized HCP experience across all channels and provide insights into content utilization, which helps support the identification of ‘next best action’ with ‘next best scientific content’ to deliver the most appropriate content to the HCP.

In recognition of HCP learning preferences and time constraints, NEJM has expanded its Original Research articles by offering both textual summaries (Research Summaries) and video summaries (QuickTake Videos).  These formats support the busy, practising clinician and map particularly well in digital engagement efforts. By working with Tangent90 to make these formats available to its clients via Trustrack, NEJM is expanding opportunities to engage physicians with its high-quality content.

“Providing the best possible access to our content is a strategic objective and delivering a better way to provide physicians access to unbiased, trusted research, supports that objective”, explains Matthew Cann, Managing Director, Research and Publishing, NEJM Group.

Additionally, Tangent90 collaborated with NEJM to extend the Tangent90 Resource Centre platform to include NEJM Group content, tagged in a manner that will expose all appropriate content, beyond the traditional Original Research article.

“We are excited to be supporting NEJM in their innovative and leading approach to digital content provision”, explained Jan van den Burg, CEO at Tangent90. “Our solutions facilitate the use of published scientific content in HCP communication, delivering on the individually expressed HCP needs, recognising the time-pressured environment HCPs work in”, he added.

“Tangent90 has many years of experience in the industry. Our solutions can be used in pharma and third-party channels. For example, our technology partnership with Veeva enables ePrint content use in approved Email, face-to-face and remote meeting content, as well as owned and third-party web channels”, he added. “Our collaboration with NEJM Group will serve up more relevant scientific content in HCP communications, enabling pharma to better serve the HCP community, which ultimately results in better patient outcomes”, he concluded.

Related news

Omnichannel metrics

Measuring omnichannel success

What does success look like? Is it simply proving return on investment – the thing all marketers talk about, and one of the hardest things to provide tangible evidence for?! Or are there other measures of success that can deliver the reassurance that the approach taken is the right one?

New technologies for HCP engagement

Is pharma investing in the right digital solutions?

Digital transformation has gathered pace in pharma and we have all been witnessing the acceleration. New technologies have been adopted to ensure HCP engagement is maintained but keeping up the understanding of innovative and emerging solutions and investing in the right technologies may prove challenging.

HCP digesting information

HCPs want snack-size content – pharma needs a new recipe

77% of HCPs use digital channels primarily for personal learning and development. Bitesize pieces of information are easier to digest and retain, and therefore, it makes perfect sense that often time-poor HCPs would prefer this method of content distribution.

Scroll to Top

Book A Demo

We use cookies to improve your experience on our website. By browsing this website, you agree to our use of cookies.